Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 9/20 | 0.38 |
| ▸ | CTSS | P25774 | 6/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28272668 | 0.87 | CA1 (0.38) | CA1CA2CA7KMT2AMEN1 | |
| SCHEMBL3105952 | 0.86 | CA1 (0.40) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL16760 | 0.86 | CA12 (0.41) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL79739 | 0.86 | CA1 (0.40) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL5966252 | 0.82 | CTSK (0.43) | CA1CA2CA7KMT2AMEN1 | |
| SCHEMBL7263399 | 0.82 | CTSK (0.41) | CA1CA2CA7KMT2AMEN1 | |
| SCHEMBL5877427 | 0.81 | CYP1A2 (0.50) | CA1CA2CA7GAACTSK | |
| SCHEMBL12942522 | 0.79 | CA1 (0.50) | CA1CA2CA7KMT2ACTSK | |
| SCHEMBL5231692 | 0.76 | KDM4E (0.36) | CA1CA2CA12 | |
| SCHEMBL2980049 | 0.76 | PTPRC (0.34) | CA2KMT2AMEN1GAACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4647424-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-11-12 | — | — | EP | disclosed |
| EP-3440097-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-23 | — | — | EP | disclosed |
| US-11352316-B2 | Opioid receptor modulators and products and methods related thereto | EPIODYNE, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210163402-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210147343-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. | 2021-05-20 | — | — | US | disclosed |
| US-10358463-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-23 | — | — | US | disclosed |
| US-10358463-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-23 | — | — | US | disclosed |
| EP-3440097-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | Bristol-Myers Squibb Company (US) | 2019-02-13 | — | — | EP | disclosed |
| CN-109311943-A | Macrocyclic inhibitors of PD-1/PD-L1 and CD80/PD-L1 protein/protein interactions | 百时美施贵宝公司 | 2019-02-05 | — | — | CN | disclosed |
| US-7141596-B2 | Inhibitors of proteins that bind phosphorylated molecules | INCYTE CORPORATION (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1675835-A1 | METHODS OF PREPARATION OF DEHYDRO-DIKETOPIPERAZINES IN LIQUID PHASE OR OF SOLID SUPPORTED PHASE | Couladouros, Elias Andrea (GR) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005123685-A1 | TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
| US-20050272778-A1 | Inhibitors of proteins that bind phosphorylated molecules | INCYTE CORPORATION | 2005-12-08 | — | — | US | disclosed |
| WO-2005035551-A2 | INHIBITORS OF PROTEINS THAT BIND PHOSPHORYLATED MOLECULES | INCYTE CORPORATION (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005020987-A1 | HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSES GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005003102-A1 | METHODS OF PREPARATION OF DEHYDRO-DIKETOPIPERAZINES IN LIQUID PHASE OR OF SOLID SUPPORTED PHASE | COULADOUROS ELIAS (GR) | 2005-01-13 | — | — | WO | disclosed |
| EP-1483270-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | Astrazeneca AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074532-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
| US-5658943-A | VASODILATOR FOR CARDIOVASCULAR DISORDER, HYPOTENSIVE AGENT | WARNER-LAMBERT COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10358463-B2 | Immunomodulators | CD274, PDCD1, PDCD1LG2 | CA1 4738/4885CA2 4861/4885CA7 4876/4885 |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | MYT1, NTMT1, MYL6 | CA1 1098/4885CA2 258/4885CA7 635/4885 |
| US-11352316-B2 | Opioid receptor modulators and products and methods related thereto | OPRM1, OPRD1, OPRK1 | CA1 2524/4885CA2 2915/4885CA7 3718/4885 |
| US-20050272778-A1 | Inhibitors of proteins that bind phosphorylated molecules | PPP3CA, PPP5C, PPM1A | CA1 4373/4885CA2 3939/4885CA7 4732/4885 |
| US-20210163402-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | OPRM1, OPRD1, OPRK1 | CA1 2524/4885CA2 2915/4885CA7 3718/4885 |
| US-20210147343-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | OPRM1, OPRD1, OPRK1 | CA1 2917/4885CA2 3082/4885CA7 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.